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Objective and methods
To describe a case of HTLV-1 associated myelopathy
(HAM/TSP) of rapid onset and progression in a renal
transplant recipient, and the initial response to empirical
treatment.
Results
A 50-year-old man was admitted with 12 weeks of evol-
ving spastic paraparesis and urinary–fecal retention, five
months after a successful living-donor renal transplanta-
tion due to end-stage chronic kidney disease. He was on
basiliximab, metilprednisolone, tacrolimus, mychophe-
nolate and prednisone for immunosupression.
The physical examination showed pyramidal syndrome
predominantly in lower limbs, with hyperalgesia and
hypersthesia. The Kurtzke’s Expanded Disability Scale
(EDSS) showed a score of 7.5. Magnetic resonance ima-
ging showed enlargement and inflammatory pattern in
whole spinal cord. HTLV-1 ELISA was positive both in
fresh blood and cerebrospinal fluid (CSF). HTLV-1 pro-
viral load by Sybr-Green quantitative real-time PCR per-
formed twice were 1879 copies/10,000 peripheral blood
lymphocytes, and 6465 copies/10,000 CSF lymphocytes.
Although HTLV-1 screening had not been performed
before transplantation neither in the donor nor in the
recipient, results were positive in a fresh blood sample
from the donor, and negative in one from the recipient
cryopreserved two years before transplantation.
The patient received empirical treatment with a pulse
of corticosteroids, zidovudine, lamivudine, prednisone
and baclofen. After one month of treatment, the EDSS
showed a score of 7.
Conclusion and interpretations
This case report shows a very acute clinical presentation
of HAM/TSP with extensive and diffuse spinal cord
involvement in an immunosuppressed patient. In ende-
mic areas, HTLV-1 screening should be included in pro-
tocols of organs’ donors and recipients before
transplantation.
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